Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (296)	10/26/2002 4:09:15 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 631

I've followed the issue pretty closely. Dr. Allison at Berkeley is an acquaintance (I hope that he'd say "friend", once he saw and recognized me, but I'd best say acquaintance), and I have followed his work. He's expressed optimism re. MEDX, in one brief discussion a couple of years ago. I've also been in-house -- on a couple of occasions -- at RGEN and talked to them about the conflict with BMY, going back about three years. And, given this effort....... I don't have a clue re. who owns what or which approach may be better. :-) The last RGEN press release on the subject...... 1. it's going to court trial, and 2. it was interesting that RGEN was not successful in throwing out the deposition of an inventor (given that I read and remember the statement correctly). I own a few RGEN shares (not a large position), waiting on the BMY verdict. I don't get it...... why would 2 mg/kg be the only dose tested in TNF receptor-treated patients, while both 2 and 10 mg/kg were tested in MTX-treated patients? Anybody know the frequency at which that 10 mg/kg slug was given in the year long study? Arthritis Rheum 2002 Oct;46(10):2565-70 Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM. Center for Biologics Evaluation and Research, FDA, Rockville, Maryland. OBJECTIVE: Two tumor necrosis factor alpha (TNFalpha) antagonists were recently licensed in the US. Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and since 1999, it has been licensed in combination with methotrexate for treatment of rheumatoid arthritis (RA). Etanercept was licensed in 1998 for treatment of RA and, more recently, for juvenile RA and psoriatic arthritis. Because of potential immunosuppression related to use of anti-TNFalpha agents, we sought to identify postlicensure cases of opportunistic infection, including histoplasmosis, in patients treated with these products. METHODS: The US Food and Drug Administration's (FDA) passive surveillance database for monitoring postlicensure adverse events was reviewed to identify all reports received through July 2001 of histoplasmosis in patients treated with either infliximab or etanercept. RESULTS: Ten cases of Histoplasma capsulatum (HC) infection were reported: 9 associated with infliximab and 1 associated with etanercept. In patients treated with infliximab, manifestations of histoplasmosis occurred within 1 week to 6 months after the first dose and typically included fever, malaise, cough, dyspnea, and interstitial pneumonitis. Of the 10 patients with histoplasmosis, 9 required treatment in an intensive care unit, and 1 died. All patients had received concomitant immunosuppressive medications in addition to infliximab or etanercept, and all resided in HC-endemic regions. CONCLUSION: Postlicensure surveillance suggests that acute life-threatening histoplasmosis may complicate immunotherapy with TNFalpha antagonists, particularly infliximab. Histoplasmosis should be considered early in the evaluation of patients who reside in HC-endemic areas in whom infectious complications develop during treatment with infliximab or etanercept.

To: Icebrg who wrote (296)	1/13/2003 7:11:58 AM
From: Icebrg	Respond to of 631

REMICADE FOR SJOGREN SYNDROME ARTHRITIS AND RHEUMATISM, December 2002;46:3301-3303: Johnson & Johnson’s Remicade (infliximab) demonstrated a positive treatment effect for patients with active primary Sjogren syndrome. Remicade is indicated in specific clinical scenarios in rheumatoid arthritis and Crohn disease. Sjogren syndrome is an autoimmune disease typically manifesting as the combination of dry eyes, dry mouth, and another autoimmune disease of connective tissues such as rheumatoid arthritis (typically), lupus, scleroderma, or polymyositis. Belgian researchers had conducted a 3-month pilot study of 16 patients treated with infliximab 3 mg/kg administered in three separate infusions at weeks 0, 2, and 6. The safe therapy led to rapid, sustained improvements in clinical and functional outcomes studied. These results prompted the investigators to extend the protocol, effectively testing an infliximab maintenance regimen, to additional infusions every 12 weeks for 1 year. 10 of the original 16 study subjects participated the maintenance program. The improved disease outcomes prompted by the original infusions lasted 9 weeks prior to symptom reemergence, most commonly dry mouth. 3 subjects remained symptom-free for one year after the initial regimen. After 1 year of maintenance therapy, all 10 patients experienced statistically significant clinical improvements. Comments: There are as far as I know no real treatment options available for people suffering from Sjogren's syndrome. So, these are good news indeed.